Empagliflozin in patients with chronic kidney disease

<p><strong>Background</strong></p> The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range o...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Herrington, WG, Staplin, N, Green, JB, Hauske, SJ, Emberson, J, Preiss, D, Judge, P, Mayne, K, Ng, S, Sammons, E, Zhu, D, Hill, M, Stevens, W, Wallendszus, K, Brenner, S, Cheung, AK, Liu, Z-H, Li, J, Hooi, LS, Wen Liu, Kadowaki, T, Nangaku, M, Levin, A, Cherney, D, Maggioni, AP, Pontremoli, R, Deo, R, Goto, S, Rossello, X, Tuttle, KR, Steubl, D, Petrini, M, Massey, D, Eilbracht, J, Brueckmann, M, Landray, M, Baigent, C, Haynes, R
Altri autori:	EMPA-KIDNEY Collaborative Group
Natura:	Journal article
Lingua:	English
Pubblicazione:	Massachusetts Medical Society 2022

Empagliflozin in patients with chronic kidney disease

Documenti analoghi